These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16764756)

  • 21. The role of new agents in the treatment of non-small cell lung cancer.
    Bröker LE; Giaccone G
    Eur J Cancer; 2002 Dec; 38(18):2347-61. PubMed ID: 12460778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.
    Formisano L; Jansen VM; Marciano R; Bianco R
    Anticancer Agents Med Chem; 2018; 18(9):1235-1240. PubMed ID: 28901258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S50. PubMed ID: 21884998
    [No Abstract]   [Full Text] [Related]  

  • 24. [III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges].
    Hirai F
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):940-3. PubMed ID: 26353391
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of new first-line therapeutic options for non-small-cell lung cancer.
    Crinò L; Foglietta J; Hamzaj A
    Lung Cancer; 2006 Dec; 54 Suppl 2():S19-24. PubMed ID: 17056151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future developments in the treatment of lung cancer.
    Hirsch FR; Fischer JR; Niklinski J; Zöchbaüer-Müller S
    Lung Cancer; 2002 Dec; 38 Suppl 3():S81-5. PubMed ID: 12468154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
    Girard N
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing targeted therapies for lung cancer.
    Gandara DR
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract]   [Full Text] [Related]  

  • 29. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.
    Takayuki N; Keiko T; Junji U; Yoshiko K; Nobuyo T; Tadaaki Y; Koichi T
    Biomed Res Int; 2018; 2018():8202971. PubMed ID: 29854794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-small cell lung cancer: from cytotoxic systemic chemotherapy to molecularly targeted therapy.
    Cesario A; Trombino S; Galetta D; Margaritora S; Murolo C; Dominioni L; Imperatori A; Festi L; Granone P; Russo P
    Curr Med Chem Anticancer Agents; 2004 May; 4(3):231-45. PubMed ID: 15134502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapy in non-small-cell lung cancer.
    Herbst RS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):19-24. PubMed ID: 12375797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
    Lind JS; Herder GJ; Smit EF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(16):928-32. PubMed ID: 18561788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?
    Raben D; Ryan A
    Clin Lung Cancer; 2005 Nov; 7(3):175-9. PubMed ID: 16354311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.
    Socinski MA; Chaft JE; Levy B; Riely GJ; Langer CJ; Perez-Soler R; Middleton DL; Gracie-King L; Healy LM
    Clin Lung Cancer; 2017 May; 18(3):255-258. PubMed ID: 28188100
    [No Abstract]   [Full Text] [Related]  

  • 37. Current management of advanced non-small cell lung cancer: targeted therapy.
    Isobe T; Herbst RS; Onn A
    Semin Oncol; 2005 Jun; 32(3):315-28. PubMed ID: 15988686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
    Pilotto S; Novello S; Peretti U; Kinspergher S; Ciuffreda L; Milella M; Carbognin L; Vavalà T; Ferrara R; Caccese M; Tortora G; Bria E
    Expert Opin Investig Drugs; 2015; 24(9):1143-61. PubMed ID: 26065529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.